These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30827673)

  • 1. E3 ubiquitin ligases in B-cell malignancies.
    Choi J; Busino L
    Cell Immunol; 2019 Jun; 340():103905. PubMed ID: 30827673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3 ubiquitin ligases, the powerful modulator of innate antiviral immunity.
    Zheng Y; Gao C
    Cell Immunol; 2019 Jun; 340():103915. PubMed ID: 31054776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
    Landré V; Rotblat B; Melino S; Bernassola F; Melino G
    Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
    Guharoy M; Bhowmick P; Tompa P
    J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
    Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
    Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
    Daks AA; Melino D; Barlev NA
    Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
    Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
    Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitin-mediated NFκB degradation pathway.
    Xu H; You M; Shi H; Hou Y
    Cell Mol Immunol; 2015 Nov; 12(6):653-5. PubMed ID: 25345807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA; Smith PG; Rolfe M
    Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein-Protein Interaction Inhibitors.
    Weber E; Rothenaigner I; Brandner S; Hadian K; Schorpp K
    SLAS Discov; 2017 Mar; 22(3):316-323. PubMed ID: 27909234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of ubiquitin ligases in cancer.
    Qi J; Ronai ZA
    Drug Resist Updat; 2015 Nov; 23():1-11. PubMed ID: 26690337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Multifaceted Role of the Ubiquitin Proteasome System in Pathogenesis and Diseases.
    Stekel Z; Sheng Y; Zhang W
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
    Nguyen HC; Wang W; Xiong Y
    Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-κB1 p105 to p50: A potential for a tumor-suppressive PROTAC.
    Goldhirsh G; Kravtsova-Ivantsiv Y; Satish G; Ziv T; Brik A; Ciechanover A
    Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34873064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on ubiquitin ligases: Orchestrators of plant resilience in adversity.
    Suranjika S; Barla P; Sharma N; Dey N
    Plant Sci; 2024 Oct; 347():112180. PubMed ID: 38964613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.